The federal government has split cannabis into two tracks. FDA-approved drug products containing marijuana and marijuana activity tied to a qualifying state-issued medical marijuana license under the new federal framework now occupy a different federal posture, while broader marijuana remains in Schedule I pending further proceedings.¹ That split is real, immediate, and carries tax, compliance, timing, and enforcement consequences. Operators who treat it as “just another news story” or assume “it will all work out” are making a costly mistake.
The Practical Business Choices in Front of You:
1. Register or Not?
State-licensed medical operators can seek expedited DEA registration through the new Medical Marijuana Dispensary Registration Portal.² The federal rule creates a new medical registration pathway, and qualifying businesses should evaluate that process immediately.³
Trulieve Cannabis Corp. (TCNNF) announced on April 29 that it had filed DEA registration applications for more than 200 dispensaries.⁴ That does not mean every operator must copy Trulieve’s structure or timeline. It does mean sophisticated companies are already acting on the new federal framework instead of waiting.⁵
2. Restructure or Not? (Mixed Operators)
If your business serves both medical and recreational customers, the IRS has not yet issued final apportionment rules for shared expenses.⁶ Treasury has signaled forthcoming guidance on allocating overhead, rent, payroll, and other costs between the now-favored medical line and the still-burdened recreational line.⁷
Smart operators are already modeling entity separation — distinct LLCs, subsidiaries, or cleaner internal accounting structures where state law permits. This simplifies compliance, reduces IRS dispute risk, and better protects the medical side’s 280E treatment.⁸ Waiting passively for final IRS guidance is risky.⁹
3. Shift Capacity to Medical or Stay Put?
Vertical operators with cultivation, processing, or dispensary capacity face a strategic decision: how much of their footprint should be dedicated to the newly favored medical track? State medical licenses can often be expanded or more fully utilized. Shifting marginal production or retail capacity into medical channels may deliver meaningful federal tax advantages and compliance breathing room while the broader rescheduling fight continues.¹⁰
Every day of delay is another day of unnecessary 280E exposure on the recreational side and another day in which faster-moving competitors gain ground.¹¹
Why You Cannot Afford to “Wait and See”
The May 13 House Appropriations Committee markup of the FY2027 CJS bill contains Section 591 — a rider that would bar the use of any appropriated funds to reschedule marijuana or remove it from the schedules.¹² If that language survives and is ultimately enacted, it would most clearly threaten further federal rescheduling work, including the June 29–July 15 ALJ hearing on broader reform.¹³ Even if the rider is later stripped in conference, the uncertainty it injects is immediate and expensive.¹⁴
Operators who avoid studying the actual statutes, Federal Register notices, appropriations marks, and IRS guidance are effectively outsourcing their risk management to hope. That is not a business strategy. It is a liability.
Real-world consequences of inattention
• Delayed evaluation of DEA registration → lost time inside the new federal medical framework¹⁵
• Unmodeled expense allocation → surprise tax exposure or IRS disputes¹⁶
• Failure to cleanly distinguish medical and recreational operations → more complicated 280E treatment and higher audit risk¹⁷
• Inability to shift capacity or update planning assumptions → competitive disadvantage against faster operators
The laws are complicated by design. The timelines are short. The stakes — cash flow, tax treatment, compliance posture, and long-term viability — are real. Ignoring the details does not make them disappear; it simply guarantees you will be reacting instead of positioning.
What Operators Should Do This Week
• Read the primary sources first. Start with the DOJ final order,¹⁸ the Federal Register notices,¹⁹ the DEA portal guidance,²⁰ and the actual text of Section 591.²¹ Skim summaries later.
• Model three scenarios. (1) Full medical registration and separation; (2) partial capacity shift; (3) status quo with continued 280E exposure through 2027.
• Engage counsel and tax advisors immediately. Registration strategy, apportionment methodology, restructuring, and DEA compliance are not DIY projects.²²
• Track the May 13 markup and June hearing closely. The appropriations and administrative processes are running in parallel and can reshape the landscape overnight.²³
• Document everything contemporaneously. Clear records of how you classify operations, allocate costs, and evaluate registration options are among the best protections you can create.²⁴
The federal rescheduling shift is not a distant policy debate. It is a live regulatory change already reshaping tax treatment, compliance obligations, and competitive positioning.²⁵ Operators who treat it as such — who read the actual laws, model the outcomes, and act on the details — will be better positioned when the dust settles.
The work is tedious. The payoff is survival and competitive advantage. Choose accordingly.
Footnotes
¹ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements, 91 Fed. Reg. 22,714 (Apr. 28, 2026) (to be codified at 21 C.F.R. pts. 1300, 1301, 1308, 1312).
² U.S. Drug Enforcement Admin., Medical Marijuana Registration Portal Notice; see also Nate Raymond, U.S. DEA Medical Marijuana Registration Portal to Launch Wednesday, Reuters (Apr. 27, 2026).
³ 91 Fed. Reg. at 22,714–22,723.
⁴ Trulieve Cannabis Corp., Press Release, Trulieve Announces Applications Filed for DEA Registration of State Licensed Medical Marijuana Businesses (Apr. 29, 2026), https://investors.trulieve.com/2026-04-29-Trulieve-Announces-Applications-Filed-for-DEA-Registration-of-State-Licensed-Medical-Marijuana-Businesses.
⁵ 21 C.F.R. § 1301.13(k).
⁶ U.S. Dep’t of the Treasury, Press Release SB0471, Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling (Apr. 23, 2026), https://home.treasury.gov/news/press-releases/sb0471.
⁷ Id.
⁸ I.R.C. § 280E; Treasury Press Release SB0471, supra note 6.
⁹ Treasury Press Release SB0471, supra note 6.
¹⁰ 21 U.S.C. § 823; 91 Fed. Reg. at 22,722.
¹¹ I.R.C. § 280E.
¹² H.R. ___ (CJS Appropriations Act, 2027), § 591 (subcomm. mark, Apr. 30, 2026).
¹³ Schedules of Controlled Substances: Rescheduling of Marijuana, 91 Fed. Reg. 22,777 (Apr. 28, 2026) (notice of hearing).
¹⁴ Id.
¹⁵ 21 C.F.R. § 1301.13(k); U.S. Drug Enforcement Admin., supra note 2.
¹⁶ Treasury Press Release SB0471, supra note 6.
¹⁷ I.R.C. § 280E; Treasury Press Release SB0471, supra note 6.
¹⁸ U.S. Dep’t of Justice, Press Release, Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-Issued License in Schedule III (Apr. 23, 2026), https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana.
¹⁹ 91 Fed. Reg. 22,714, supra note 1; 91 Fed. Reg. 22,777, supra note 13.
²⁰ U.S. Drug Enforcement Admin., supra note 2.
²¹ H.R. ___ § 591, supra note 12.
²² 21 C.F.R. pts. 1301, 1308, 1317.
²³ House Comm. on Appropriations, Full Committee Markup of FY2027 CJS Bill (scheduled May 13, 2026).
²⁴ I.R.C. § 162; Treasury Press Release SB0471, supra note 6.
²⁵ 21 U.S.C. § 812(b)(3); I.R.C. § 280E.
WeedPress: The Paper Trail 
Leave a comment